Erythropoietin Drugs Market Estimated to Reach USD 14.3 billion, Advancing at a CAGR of 3.8% by 2034: Transparency Market Research Inc.
September 18, 2024 07:05 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The global erythropoietin drugs market is estimated to surge at a CAGR of 3.8% from 2024...
Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference
September 12, 2024 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Culture Biosciences and Google Cloud Announce Collaboration to Revolutionize Bioprocess Development
September 10, 2024 10:00 ET
|
Culture Biosciences
SAN FRANCISCO, CALIFORNIA, UNITED STATES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Culture Biosciences—a leader in automated bioprocess development, optimization and data science —announces a strategic...
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
September 09, 2024 16:05 ET
|
Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160...
Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR Report
September 05, 2024 06:00 ET
|
FACT.MR
Rockville, MD, Sept. 05, 2024 (GLOBE NEWSWIRE) -- According to a new industry report released by Fact.MR, revenue from the global pseudarthrosis treatment market is estimated to reach US$ 879.4...
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024
September 03, 2024 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Lifecore Biomedical Announces Chief Financial Officer Transition
August 29, 2024 07:00 ET
|
Lifecore Biomedical, Inc.
CHASKA, Minn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization...
Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update
August 26, 2024 17:23 ET
|
Lifecore Biomedical, Inc.
-- Recorded Revenues of $128.3 million for Fiscal 2024; Year-Over-Year Increase of 24.2% ---- High Value Pipeline Continues to Advance Toward Commercialization ---- State-of-the-Art Technology...